Stomach Cancer Treatment in China

Stomach cancer is the fifth most common cancer worldwide, with about 980,000 new cases a year, around 71% of them in Asia [1]. China recorded about 359,000 new cases in 2022 [2]. Large Chinese trials have shaped treatment: CLASS-01 showed that laparoscopic distal gastrectomy is as effective as open surgery for locally advanced disease [3] [4], and RESOLVE showed that S-1 plus oxaliplatin (SOX) chemotherapy, given around or after surgery, improved 5-year survival compared with standard capecitabine plus oxaliplatin after surgery [5]. In June 2026, China approved satri-cel, the world's first CAR-T therapy for a solid tumour, for advanced CLDN18.2-positive stomach cancer [10] [17]. We can send your records to Prof. Jiafu Ji or Prof. Lin Shen of Peking University Cancer Hospital, who led the RESOLVE and satri-cel trials, or to Prof. Rui-Hua Xu of Sun Yat-sen University Cancer Center, get you a written treatment opinion, and arrange treatment in China if you decide to come.

Specialists
Prof. Jiafu Ji, Prof. Lin Shen, Prof. Rui-Hua Xu
Hospitals
Peking University Cancer Hospital; Sun Yat-sen University Cancer Center
Typical time in China
About 1–2 weeks for endoscopic removal; 3–4 weeks for surgery; about 3 months with chemotherapy before surgery
Written opinion
US$199, within 5 working days, with a cost estimate
Upload records for a specialist opinionNo travel needed for the opinion. Full refund if the specialist cannot accept your case.

Why patients consider China for stomach cancer

1. A large number of patients

China recorded about 359,000 new stomach cancer cases in 2022 [2], and around 71% of stomach cancers worldwide occur in Asia [1].

2. Trials led or joined by Chinese teams

SettingStudyResult
Locally advanced: laparoscopic or open surgeryCLASS-01, randomised, 1,056 patients, 14 centres in China, JAMA 2019 and JAMA Surgery 2022 [3] [4]3-year disease-free survival 76.5% laparoscopic vs 77.8% open — not inferior; 5-year overall survival 72.6% vs 76.3%, no significant difference
Locally advanced (cT4a N+ or cT4b): chemotherapy around surgeryRESOLVE, phase III, 1,094 patients, led by Peking University Cancer Hospital, Lancet Oncology 2025 [5]5-year overall survival 60.0% with perioperative SOX and 61.0% with SOX after surgery, vs 52.1% with capecitabine plus oxaliplatin after surgery
Advanced, first line: immunotherapy plus chemotherapySintilimab plus chemotherapy (ORIENT-16), 650 patients, 62 hospitals in China, JAMA 2023 [6]Median overall survival 15.2 vs 12.3 months; 18.4 vs 12.9 months when PD-L1 CPS was 5 or more
Advanced, first line: immunotherapy plus chemotherapyTislelizumab plus chemotherapy (RATIONALE-305), 997 patients, 146 centres in Asia, Europe and North America, BMJ 2024 [7]Median overall survival 15.0 vs 12.9 months in all patients
Advanced, first line: bispecific antibody plus chemotherapyCadonilimab (PD-1/CTLA-4) plus chemotherapy, 610 patients, Nature Medicine 2025 [8]Median overall survival 14.1 vs 11.1 months
CLDN18.2-positive, HER2-negative, advanced, first lineZolbetuximab plus CAPOX (GLOW), global phase III, 507 patients, Nature Medicine 2023 [9]Median overall survival 14.4 vs 12.2 months
CLDN18.2-positive, after at least two lines of treatmentSatri-cel (CAR-T) vs physician's choice, randomised, 156 patients, China, Lancet 2025 [10]Median progression-free survival 3.25 vs 1.77 months; the first randomised CAR-T trial in a solid tumour; grade 3 or higher side effects in 99% (mainly low blood counts) and cytokine release syndrome in 95%

More on Chinese PD-1 drugs and their prices: cancer immunotherapy in China.

3. Dedicated services for international patients

Sun Yat-sen University Cancer Center has an International Medical Center with its own area, where outpatients can book a named specialist [14].

Treatment options

Your plan is decided by the doctor after reviewing your endoscopy and pathology reports, CT scans and biomarker tests. The table shows common approaches.

SituationCommon treatmentTreatment lengthApproximate stay in China
Early, limited to the inner lining, suitable for endoscopic removalEndoscopic resection (ESD or EMR) [13]Usually a few days in hospitalAbout 1–2 weeks
Locally advanced, operableD2 gastrectomy, laparoscopic or open [3], with chemotherapy before and after or after surgery, such as SOX or capecitabine plus oxaliplatin [5] [12]About 1–2 weeks in hospital after surgery; chemotherapy in 3-week cycles for about 6 months [5]About 3–4 weeks for surgery and recovery; about 3 months if 3 cycles of chemotherapy are given before surgery [5]
Advanced, HER2-negativeChemotherapy plus PD-1 immunotherapy, depending on PD-L1 [6] [7] [12]; if CLDN18.2-positive, zolbetuximab plus chemotherapy may be considered [9]Continuous, with regular assessmentFirst cycles in China; whether treatment can continue at home is decided by the doctor
Advanced, HER2-positiveTrastuzumab plus chemotherapy [12]ContinuousAs above
After at least two lines of treatment, CLDN18.2-positive (2+ or stronger in at least 40% of tumour cells)Satri-cel CAR-T therapy [10] [11]; see CAR-T in ChinaCell collection, manufacturing, infusion and monitoringAbout 2–3 months

Hospital stays and times in China are typical estimates. Your written opinion gives the plan for your case.

Specialists we can connect you with

These specialists can provide a written opinion or an outpatient appointment through us. This page was written by our medical team based on published research.

Prof. Jiafu Ji

Prof. Jiafu Ji

Academician of the Chinese Academy of Engineering; Professor and Chief Physician · Gastrointestinal Cancer Center, Peking University Cancer Hospital

Surgery and multimodality treatment of stomach cancer

  • Lancet Oncology 2025 (senior author): Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): final report of a randomised, open-label, phase 3 trial — PubMed 39952264
  • Nature Medicine 2025 (senior author): First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial — PubMed 39843940
  • JAMA Surgery 2019 (senior author): Assessment of Laparoscopic Distal Gastrectomy After Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: A Randomized Clinical Trial — PubMed 31553463
Request a written opinion from Prof. Jiafu Ji
Prof. Lin Shen

Prof. Lin Shen

Director, Department of Gastrointestinal Oncology, and Director, Phase I Clinical Trial Ward; Professor and Chief Physician · Department of Gastrointestinal Oncology, Peking University Cancer Hospital

Drug treatment of stomach and other gastrointestinal cancers, including immunotherapy and CLDN18.2 CAR-T therapy

  • Lancet 2025 (senior author): Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial — PubMed 40460847
  • Nature Medicine 2025 (first author): First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial — PubMed 39843940
  • Nature Medicine 2024 (senior author): Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results — PubMed 38830992
Request a written opinion from Prof. Lin Shen
Prof. Rui-Hua Xu

Prof. Rui-Hua Xu

President of Sun Yat-sen University Cancer Center; Academician of the Chinese Academy of Engineering; Professor · Department of Medical Oncology, Sun Yat-sen University Cancer Center

Drug treatment of stomach and other gastrointestinal cancers

  • Nature Medicine 2023 (senior author): Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial — PubMed 37524953
  • Cancer Communications 2024 (senior author): The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023 — PubMed 38160327
  • Journal of Hematology & Oncology 2023 (senior author): Gastric cancer treatment: recent progress and future perspectives — PubMed 37245017
Request a written opinion from Prof. Rui-Hua Xu

Hospitals

Peking University Cancer Hospital, Beijing

Sun Yat-sen University Cancer Center, Guangzhou

Read the hospital profile

Costs

Your personal cost estimate is included in the specialist's written opinion.

ItemChina
Specialist's written opinionUS$199
First visit, endoscopic resection, gastrectomy, chemotherapyQuoted individually in your cost estimate
Immunotherapy (per cycle)See Chinese PD-1 drug prices
Satri-cel CAR-T (list price per dose)RMB 990,000 [16]
Accommodation near the hospital (28 nights)Near Peking University Cancer Hospital, Beijing: budget hotel US$1,500–1,950. Near SYSUCC, Guangzhou: apartment-style room with fridge and washing machine, mostly US$750–1,000.
Food, local transport and other living costs (per person, per month)About US$550–600 (around RMB 4,000)

Accommodation: Trip.com prices for rooms within about 800 m (Beijing) or 400 m (Guangzhou) of the hospital, 28 nights from 7 December 2026, checked on 12 November 2026, including taxes and the discounts shown at the time. Prices change with dates and season. Living costs: Numbeo (Beijing, Guangzhou), November 2026. More on accommodation.

From first contact to starting treatment

  1. Send your records
    Endoscopy and pathology reports, contrast CT, HER2, PD-L1 and CLDN18.2 results if available, treatment history. Same day
  2. Initial review
    A medical coordinator checks and translates your records. Within 24 hours
  3. Specialist's written opinion
    Recommended treatment and a cost estimate. Within 5 working days of receiving your complete records
  4. Travel arrangements
    Appointment, hospital invitation letter, visa support, accommodation and airport pickup.
  5. Hospital visit
    Consultation with the specialist, with additional tests if needed.
  6. Treatment starts
    A coordinator and interpreter support you throughout.

Frequently asked questions

What is the survival rate for stomach cancer?

It depends on the stage. In the CLASS-01 trial (tumours T2–T4a without bulky lymph nodes or spread, treated with D2 surgery), 5-year overall survival was about 73–76% [4]. In the RESOLVE trial, which included more advanced local disease (cT4a N+ or cT4b), 5-year overall survival was 52–61% depending on the chemotherapy given [5].

Is laparoscopic (keyhole) surgery as good as open surgery?

In CLASS-01, carried out at experienced high-volume centres in China, 3-year disease-free survival after laparoscopic distal gastrectomy was not inferior to open surgery, and 5-year overall survival did not differ significantly [3] [4].

What is CLDN18.2 testing, and why does it matter?

CLDN18.2 (claudin 18.2) is a protein found on many stomach cancer cells. It is tested on tumour tissue. Patients whose tumours are positive may be offered zolbetuximab with chemotherapy [9] and, after at least two earlier treatments, the CAR-T therapy satri-cel [10]. Please keep your pathology slides or tissue blocks.

Can international patients receive satri-cel in China?

Satri-cel was approved in China in June 2026 for CLDN18.2-positive, HER2-negative advanced stomach or gastro-oesophageal junction adenocarcinoma after at least two lines of treatment [11]. Approved CAR-T products have already been given to international patients in China — for example, a patient from Singapore was treated in Shanghai in 2023 [18]. Prof. Lin Shen, who led the satri-cel trial, is one of the specialists we can connect you with. See also CAR-T therapy in China.

How long will I need to stay in China?

Usually about 1–2 weeks for endoscopic removal and about 3–4 weeks for surgery and recovery. If chemotherapy is given before surgery (3 cycles over about 9 weeks [5]), plan for about 3 months.

I do not speak Chinese. How will I communicate?

Our medical coordinators work with you in English (or Russian) throughout, and an interpreter accompanies you to appointments.

How do I pay? Can I use insurance?

Hospitals accept self-payment. Some international departments in China also accept commercial insurance; whether your insurer can settle bills directly depends on your policy, and we check this before you travel.

Can I get a specialist opinion without travelling to China first?

Yes. Upload your records and one of the specialists above will give a written opinion. You can then decide whether to come to China.

Leading hospitals and specialists for stomach cancer in China

From our directory of leading Chinese hospitals: where senior specialists list stomach cancer as a clinical focus, sorted by their first- or senior-author papers on it since 2016. This is not a quality ranking. How we build this directory

#HospitalCitySpecialistsPapers since 2016
1Zhejiang Cancer Hospital
Department of Gastric Surgery · Department of Radiation Oncology
Hangzhou32162
2Cancer Hospital, Chinese Academy of Medical Sciences (National Cancer Center)
Department of Pancreatic and Gastric Surgery · Department of Medical Oncology
Beijing25156
3Harbin Medical University Cancer Hospital
Department of Gastrointestinal Surgery · Department of Gastroenterology
Harbin34140
4Sun Yat-sen University Cancer Center
Department of Medical Oncology · Department of Gastric Surgery
Guangzhou2899
5Fudan University Shanghai Cancer Center
Department of Gastric Surgery · Department of Medical Oncology
Shanghai3186
6Henan Cancer Hospital
Department of General Surgery · Department of Integrated Traditional Chinese and Western Medicine Oncology
Zhengzhou2879
7Peking University Cancer Hospital
Gastrointestinal Tumor Center, Ward 1 · Department of Gastrointestinal Medical Oncology
Beijing3354
8Liaoning Cancer Hospital & Institute
Department of Gastric Surgery · Department of Medical Oncology
Shenyang3953
9Tianjin Medical University Cancer Institute & Hospital
Department of Gastric Oncology · Department of Medical Oncology for Digestive Tumors
Tianjin2048
10Hunan Cancer Hospital
Department of Medical Oncology · Department of Abdominal Surgery
Changsha3144
11Fujian Cancer Hospital
Department of Gastrointestinal Tumor Surgery · Department of Radiation Oncology
Fuzhou1741
12Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Department of Oncology (Chemotherapy and Radiotherapy)
Shanghai139
13Jiangsu Cancer Hospital
Department of General Surgery · Department of Medical Oncology
Nanjing2338
14West China Hospital, Sichuan University
Department of Abdominal Oncology · Medical Oncology (II)
Chengdu731
15Cancer Hospital of Shandong First Medical University (Shandong Cancer Hospital)
Department of Gastric Surgery · Department of Thoracic Radiation Oncology I
Jinan1830

Senior specialists in our directory

Prof. Yingwei Xue(Harbin Cancer Hospital) · Prof. Yantao Tian(CHCAMS) · Prof. Jingyu Deng(TMUCIH) · Dr. Yingtai Chen(CHCAMS) · Dr. Zhiyuan Xu(Zhejiang Cancer Hospital) · Prof. Miaozhen Qiu(SYSUCC) · Dr. Hua Xiao(Hunan Cancer Hospital) · Dr. Zhi Peng(Peking University Cancer Hospital) · Dr. Pengfei Yu(Zhejiang Cancer Hospital) · Dr. Shuqiang Yuan(SYSUCC) · Prof. Yan Zhao(Liaoning Cancer Hospital & Institute) · Dr. Lin Yang(CHCAMS)

We have not necessarily worked with these doctors. Specialists we can connect you with are listed above.

Get a specialist's written opinion

Upload your endoscopy, pathology and CT reports. A medical coordinator will reply within 24 hours and pass your records to the specialist.

Start here

References

  1. International Agency for Research on Cancer. GLOBOCAN 2024 stomach cancer fact sheet: 980,286 new cases worldwide; 70.8% in Asia. https://gco.iarc.who.int/media/globocan/factsheets/cancers/7-stomach-fact-sheet.pdf
  2. International Agency for Research on Cancer. GLOBOCAN 2022 China fact sheet: 358,672 new stomach cancer cases. https://gco.iarc.who.int/media/globocan/factsheets/populations/160-china-fact-sheet.pdf
  3. Yu J, et al. Effect of laparoscopic vs open distal gastrectomy on 3-year disease-free survival in patients with locally advanced gastric cancer: the CLASS-01 randomized clinical trial. JAMA. 2019. PMID 31135850. https://pubmed.ncbi.nlm.nih.gov/31135850/
  4. Huang C, et al. Laparoscopic vs open distal gastrectomy for locally advanced gastric cancer: five-year outcomes from the CLASS-01 randomized clinical trial. JAMA Surg. 2022. PMID 34668963. https://pubmed.ncbi.nlm.nih.gov/34668963/
  5. Zhang X, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): final report. Lancet Oncol. 2025. PMID 39952264. https://pubmed.ncbi.nlm.nih.gov/39952264/
  6. Xu J, et al. Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial. JAMA. 2023. PMID 38051328. https://pubmed.ncbi.nlm.nih.gov/38051328/
  7. Qiu MZ, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305. BMJ. 2024. PMID 38806195. https://pubmed.ncbi.nlm.nih.gov/38806195/
  8. Shen L, et al. First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial. Nat Med. 2025. PMID 39843940. https://pubmed.ncbi.nlm.nih.gov/39843940/
  9. Shah MA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023. PMID 37524953. https://pubmed.ncbi.nlm.nih.gov/37524953/
  10. Qi C, et al. Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial. Lancet. 2025. PMID 40460847. https://pubmed.ncbi.nlm.nih.gov/40460847/
  11. 21st Century Business Herald, 22 June 2026: China's National Medical Products Administration approves satricabtagene autoleucel, the world's first CAR-T therapy approved for a solid tumour (in Chinese). https://m.21jingji.com/article/20260622/herald/b2fac415c3ee78b537e04a93ae0fafd2_zaker.html
  12. Wang FH, et al. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2023. Cancer Commun. 2024. PMID 38160327. https://pubmed.ncbi.nlm.nih.gov/38160327/
  13. Ono H, et al. Guidelines for endoscopic submucosal dissection and endoscopic mucosal resection for early gastric cancer (second edition). Dig Endosc. 2021. PMID 33107115. https://pubmed.ncbi.nlm.nih.gov/33107115/
  14. Sun Yat-sen University Cancer Center. International Medical Center. https://english.sysucc.org.cn/index_79.aspx
  15. Fudan University Hospital Management Institute, China Hospital Specialty Reputation Ranking 2023 (oncology), as reported by The Paper. https://www.thepaper.cn/newsDetail_forward_25427491
  16. Huxiu: satricabtagene autoleucel priced at RMB 990,000 (in Chinese). https://www.huxiu.com/article/4869701.html
  17. China News Service, 22 June 2026, citing the Shanghai Science and Technology Commission: satricabtagene autoleucel approved by China's National Medical Products Administration as the world's first CAR-T therapy for solid tumours (in Chinese). https://www.chinanews.com.cn/sh/2026/06-22/10645095.shtml
  18. Jiahui International Hospital, Shanghai: first foreign patient in China treated with axicabtagene ciloleucel (cells collected 19 July 2023, infused 21 August 2023, discharged 13 September 2023). https://jiahui.com/en/news/133